According to Xuantai Pharmaceutical's announcement, Nanjing Cihe Venture Capital Partnership, a shareholder of the company, completed the procedure for cancelling the pledge of some shares on October 16, 2026. This time, 10 million shares were released from the pledge, accounting for 50.00% of its total shareholding and 2.21% of the company's total share capital. As of the disclosure date of the announcement, Qihe Venture held 20 million shares of the company, accounting for 4.41% of the company's total share capital; after the pledge was lifted, it pledged a total of 10 million shares, accounting for 50.00% of its total shareholding and 2.21% of the company's total share capital.

According to Xuantai Pharmaceutical's announcement, Nanjing Cihe Venture Capital Partnership, a shareholder of the company, completed the procedure for cancelling the pledge of some shares on October 16, 2026. This time, 10 million shares were released from the pledge, accounting for 50.00% of its total shareholding and 2.21% of the company's total share capital. As of the disclosure date of the announcement, Qihe Venture held 20 million shares of the company, accounting for 4.41% of the company's total share capital; after the pledge was lifted, it pledged a total of 10 million shares, accounting for 50.00% of its total shareholding and 2.21% of the company's total share capital.